DYN Q2 2016 Earnings — Dyne Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

DYNDyne Therapeutics, Inc.

$3B

Q2 2016 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$166M-89.8% YoY

Gross Profit

-$327M-197.0% margin

Operating Income

-$552M-332.5% margin

Net Income

-$803M-483.7% margin

EPS (Diluted)

$-6.81

QoQ Revenue Growth

-1.2%

Cash Flow

Operating Cash Flow

$126M

Free Cash Flow

-$33M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$13.2B

Total Liabilities

$10.7B

Stockholders' Equity

$2.5B

Cash & Equivalents

$1.1B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$166M	$1.6B	-89.8%
Gross Profit	-$327M	$1.1B	-129.0%
Operating Income	-$552M	$10M	-5620.0%
Net Income	-$803M	$388M	-307.0%